Overview

A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan

Status:
Enrolling by invitation

Trial end date:
2024-09-30

Target enrollment:

Participant gender:

Summary

This study is conducted in Asia. Tha aim of this study is to investigate Safety and Effectiveness of NovoThirteen® (rFXIII) during treatment of congenital FXIII deficiency in Japan.

Details

Lead Sponsor:

Novo Nordisk A/S